Clearmind Medicine Advances CMND-100 for Alcohol Use Disorder Treatment in 2025

Clearmind Medicine Inc., a clinical-stage biotech company, reflects on a year of significant progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Key 2025 highlights include the multinational Phase I/IIa trial with site activations at prestigious institutions and critical milestones achieved in advancing CMND-100, a non-hallucinogenic MEAI-based oral compound designed to address AUD.